Physician profile
Adrianna Masters
NPI 1306265327
$3,568.34
in general payments reported to CMS, 2019-2025
22 companies · $1,255 in 2025
The $1,255 reported for 2025 was more than what 86% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.28 · 2022: $625 · 2023: $273 · 2024: $1,334 · 2025: $1,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,861.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gt Medical Technologies, INC | $1,506.57 | 2022-2025 | Gammatile |
| Novocure INC. | $702.34 | 2022-2025 | Optune, Optune Gio |
| Siemens Medical Solutions USA, INC. | $172.50 | 2024 | Varian Ethos Treatment Planning |
| Monteris Medical Corporation | $155.29 | 2022-2024 | Neuroblate |
| Telix Pharmaceuticals | $141.33 | 2025 | Illuccix |
| Merck Sharp & Dohme LLC | $116.80 | 2022-2025 | Keytruda, Welireg |
| Astrazeneca Pharmaceuticals Lp | $112.14 | 2022 | |
| Accuray Incorporated | $96.37 | 2022 | |
| Novartis Pharmaceuticals Corporation | $95.00 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $92.66 | 2025 | |
| Elekta, INC. | $81.28 | 2021 | |
| Azurity Pharmaceuticals, INC. | $67.10 | 2023-2024 | Gliadel, Vivimusta |
| Stemline Therapeutics INC. | $44.81 | 2025 | Elzonris, Orserdu |
| Sumitomo Pharma America, INC. | $41.57 | 2023-2024 | Orgovyx |
| Blueprint Medicines Corporation | $29.19 | 2025 | Ayvakit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainlab, INC. | $24.45 | 2023 | Image Guided Surgical Device |
| Coherus Oncology, INC. | $21.68 | 2023 | |
| Genzyme Corporation | $21.50 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $16.88 | 2025 | Onivyde |
| Incyte Corporation | $14.69 | 2023 | Jakafi |
| Eisai INC. | $14.19 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrianna Masters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.